Applying Therapeutic Strategies to Improve the Quality of Life in Patients with Alzheimer’s

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Biogen

Description:
Affecting an estimated 5 million people in the United States, Alzheimer’s disease is the most common form of dementia. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Currently, 26 million people worldwide have this dementia. And by the year 2050, over 15 million Americans will be affected with the disease. Alzheimer’s disease care costs $172 billion annually in the United States alone.

In clinical practice, the diagnosis is typically made on the basis of the history and findings on a Mental Status Examination. Diagnosing Alzheimer's requires careful medical evaluation, including medical history, mental status testing, physical and neurological exam, blood tests and brain imaging. The importance of early diagnosis cannot be understated. As the use of biomarkers continues to grow, the potential for catching Alzheimer’s disease even earlier is crucial to improving outcomes. Treatment for Alzheimer's disease is entering into a promising stage, with several new drugs beginning clinical trials. Many of these new therapies are based on an understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area.

Upon completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of emerging treatment options to improve the pathophysiology and management strategies for pre-symptomatic Alzheimer’s disease

  • Discuss current guidelines for the optimal early detection and management of AD

  • Examine the recent advances in technology, including imaging and biomarkers when appropriate, to improve diagnosis and monitor disease progression in AD

  • Discuss the current clinical data on the current and emerging treatment options for AD patients, including data on investigational disease-modifying therapies

  • Identify personalized therapeutic strategies to slow disease progression and improve patient quality of life
     

Faculty: Richard S. Isaacson, MD
Director of the Alzheimer’s Prevention Clinic
Weill Cornell Memory Disorders Program
Director of the Neurology Residency Training Program
Weill Cornell Medical College/New York-Presbyterian Hospital

Disclosure:

Dr. Isaacson served as a consultant for Neurotrack. That relationship was terminated at least 12 months ago. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Biogen

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue